コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 Cisplatin is widely used but highly ototoxic.
2 b being the least and gentamicin C2 the most ototoxic.
8 e models, such as systemic administration of ototoxic aminoglycosides, yield inconsistent and variabl
9 fe-threatening infections; however, they are ototoxic and cause irreversible damage to cochlear hair
10 y, with the lead compound N1MS 17 times less ototoxic and with reduced penetration of hair cell mecha
11 chloride, metabolites, and drugs such as the ototoxic anti-cancer drug cisplatin, and explore its phy
12 were cultured in media supplemented with the ototoxic antibiotic neomycin and selected pharmacologica
13 olecule tenascin and that treatment with the ototoxic antibiotic streptomycin results in a nearly com
18 sensus reached was that children who receive ototoxic cancer treatment (platinum agents, cranial irra
20 suggest that EHF thresholds and DPOAEs show ototoxic changes before hearing loss is detected by conv
21 indow membrane niche for infusion of a known ototoxic compound (sodium salicylate) at 50 nL/min for 2
25 dult human utricle and its early response to ototoxic damage using bulk and single-cell RNA-sequencin
26 ges consistent with a capacity to respond to ototoxic damage within 24 hours and potentially initiate
31 ty of auditory nerve synapses in response to ototoxic deafening and chronic electrical stimulation of
32 ination further suggests that the effects of ototoxic deafness are not identical to those of heredita
35 ed human embryonic kidney 293 cells with the ototoxic drug cisplatin markedly enhanced superoxide pro
37 tory function after hair cell loss caused by ototoxic drug damage or acoustic overstimulation, indica
39 SSNHL, intermediate in the noise-damage and ototoxic drug groups, and smallest in the ARHL group.
44 o preparation allows for detailed studies of ototoxic-drug-induced hair cell death in an adult mammal
45 neural hearing loss (SSNHL), (5) exposure to ototoxic drugs (carboplatin and/or cisplatin, vancomycin
47 who are receiving concomitantly administered ototoxic drugs are particularly at risk for developing h
49 gets, the inner hair cells (IHCs): following ototoxic drugs or acoustic overexposure, IHC death is ra
50 For example, following exposure to noise, ototoxic drugs or age, it would be highly desirable to a
53 erapies against hair cell damage (e.g., from ototoxic drugs) through targeted stimulation of S1PR2.
55 nts should be urged to avoid noise exposure, ototoxic drugs, and other factors that further damage he
56 onditioning protects against both classes of ototoxic drugs, and they suggest that sound therapy hold
57 ng loss are common results of treatment with ototoxic drugs, including the widely used aminoglycoside
58 alance deficits that arise when loud sounds, ototoxic drugs, infections, and aging cause hair cell lo
59 deficits.SIGNIFICANCE STATEMENT Loud sounds, ototoxic drugs, infections, and aging kill sensory hair
60 tem, sensory cell loss resulting from aging, ototoxic drugs, infections, overstimulation and other ca
62 hen HCs are irreversibly damaged by noise or ototoxic drugs, surrounding SCs seal the epithelial surf
63 tested in animals after exposure to noise or ototoxic drugs, which can cause deficits beyond synaptop
70 ed with a decreased risk of platinum-induced ototoxic effects among patients treated with platinum-in
74 ng platinum-based chemotherapy that compared ototoxic effects development between patients who receiv
75 tatistically significantly decreased risk of ototoxic effects during the course of platinum-based che
76 ed with protection against cisplatin-induced ototoxic effects in 2 independent cohorts (combined coho
77 c variants associated with cisplatin-induced ototoxic effects in adult testicular cancer patients.
81 t that concurrent STS for protection against ototoxic effects should be considered for patients indic
82 ctant for the prevention of platinum-induced ototoxic effects that functions by binding the platinum-
85 n patients' skin and assessments for safety (ototoxic effects, nephrotoxic effects, and autoimmune re
86 All 5 patients completed the study, and no ototoxic effects, nephrotoxic effects, or anti-laminin 3
87 inhibitor, prevents murine cisplatin-induced ototoxic effects, the findings from this study have impo
88 vidence has suggested that heavy metals have ototoxic effects, yet few epidemiological studies have i
97 s responded similarly to mice > 3 weeks from ototoxic exposure with decreased levels of prestin in th
100 challenged by damage from a variety of other ototoxic factors, including loud noise, aging, genetic d
103 or caspase activation in hair cell death and ototoxic injury that can be reduced by concurrent treatm
107 sory hair cells die after acoustic trauma or ototoxic insults, but the signal transduction pathways t
108 uildup is thought to sensitize hair cells to ototoxic insults, including the antibiotic neomycin.
112 f organ of Corti explants challenged with an ototoxic level of an inflammatory cytokine modulates NFk
113 hearing impairment, such as noise exposure, ototoxic medication use, and smoking (adjusted odds rati
115 loss cases were among those with exposure to ototoxic medications (19.6 million [range 12.6 million-2
116 tabolic causes of pulsatile tinnitus include ototoxic medications and systemic causes of high cardiac
117 that is attributable to disease sequelae or ototoxic medications contributes substantially to the gl
118 ical or accidental trauma, administration of ototoxic medications, local or systemic infections, vasc
119 nital rubella syndrome, cytomegalovirus, and ototoxic medications, specifically aminoglycosides, plat
120 umour necrosis factor alpha (TNFalpha) as an ototoxic molecule and fibroblast growth factor 2 (FGF2)
122 obramycin was not associated with detectable ototoxic or nephrotoxic effects or with accumulation of
123 nthesis, which in turn correlates with their ototoxic potential in both murine cochlear explants and
125 onstrate the efficacy of a 6-week subchronic ototoxic protocol in inducing transient and partial vest
126 , in order to identify additional markers of ototoxic risk associated with platinum-based chemotherap
127 helps reassure patients about the immediate ototoxic risks while highlighting the need for continued
129 eath from exposure to therapeutic drugs with ototoxic side effects, including aminoglycoside antibiot
130 ycoside antibiotics, such as kanamycin, have ototoxic side effects, which often result in degeneratio
132 ys initiated by neurotrophin-deprivation and ototoxic stress (e.g., CDDP) have been shown to be diffe
134 the need to investigate factors beyond age, ototoxic substances, and recreational noise- factors aff
136 nic and can be cytotoxic, nephrotoxic and/or ototoxic, which has limited their clinical development.